Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing–Remitting Multiple Sclerosis

Luca Prosperini, Vincenzo Brescia Brescia Morra, Carla Fornari (), Laura Santoni, Daria Perini, Roberto Bergamaschi and Paolo Angelo Cortesi
Additional contact information
Luca Prosperini: S. Camillo-Forlanini Hospital
Vincenzo Brescia Brescia Morra: Policlinico Federico II University Hospital
Carla Fornari: University of Milano-Bicocca
Laura Santoni: Biogen Italia
Daria Perini: Biogen Italia
Roberto Bergamaschi: IRCCS Mondino Foundation
Paolo Angelo Cortesi: University of Milano-Bicocca

PharmacoEconomics, 2025, vol. 43, issue 12, No 7, 1463-1477

Abstract: Abstract Background Advances in the availability and regimen optimization of highly effective disease-modifying treatments (DMTs) for relapsing–remitting multiple sclerosis (RRMS) have led to questions about their comparative worth. Objectives This study evaluates the costs and effects of natalizumab versus other highly effective DMTs and the impact, in terms of times and costs, of the new subcutaneous natalizumab formulation versus the intravenous formulation in patients with RRMS in Italy. Methods This is a cost-consequence analysis from the Italian national health service and societal perspectives. A Markov model was developed to assess clinical and cost outcomes related to disease and DMTs. The model simulated two scenarios: one comparing natalizumab extended-dose regimen and ofatumumab and ocrelizumab, focusing on efficacy outcomes and costs, and one comparing intravenous and subcutaneous natalizumab with a focus on administration resource consumption, times, and costs. Model input data came from the literature. Results DMTs had similar clinical and social outcomes: natalizumab slightly reduced disease progression, increased quality-adjusted life-years, and reduced the impact on days of productivity loss and informal care. Natalizumab also resulted in statistically significant 5-year cost reductions compared with ocrelizumab and ofatumumab. Subcutaneous natalizumab improved resource consumption compared with intravenous natalizumab, saving the time of healthcare professionals, patients, and caregivers and reducing administration costs. The subcutaneous formulation was associated with statistically significant total direct and indirect cost reductions at 5 years. Conclusion 6-week dosing regimen of natalizumab showed a slight improvement of clinical and social outcomes and a statistically significant cost reduction compared with ocrelizumab and ofatumumab over a 5-year simulation. Moreover, subcutaneous administration reduced administration times and costs.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-025-01539-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:12:d:10.1007_s40273-025-01539-3

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-025-01539-3

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().